Ardent Health SEC Filings

Ardent Health, Inc. reported Q3 2025 results with total revenue of $1,576,746,000 versus $1,449,817,000 a year ago. A change in accounting estimate reduced revenue by $42.6 million in the quarter after implementing a new revenue accounting system. Net (loss) income attributable to Ardent was $(23,478,000) (basic and diluted EPS $(0.17)), compared with net income of $26,322,000 (EPS $0.19) in Q3 2024.

For the first nine months, revenue reached $4,719,260,000 and net income attributable to Ardent was $90,855,000. Operating cash flow for the nine months was $247,075,000, ending cash was $609,441,000, and total assets were $5,154,373,000. The balance sheet showed long‑term debt (less current) of $1,087,023,000 and equity of $1,633,336,000.

Ardent refinanced its Term Loan B on September 18, 2025, cutting the margin by 50 bps (to Term SOFR + 2.25%) and extending maturity to September 2032. The company acquired 18 urgent care clinics on January 1, 2025 for $27.5 million. As of November 7, 2025, common shares outstanding were 143,187,681.

Ardent Health, Inc. (ARDT) furnished its third-quarter 2025 results press release. The company reported that, on November 12, 2025, it issued a press release covering financial results for the quarter ended September 30, 2025, and made it available as Exhibit 99.1 to a current report on Form 8-K under Item 2.02.

The information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to Section 18 of the Exchange Act and will only be incorporated by reference into other filings if expressly stated. The filing also lists Exhibit 104 for the cover page interactive data file. This is a routine disclosure that makes the company’s quarterly results press release part of the public record without triggering the liabilities associated with filed materials.

Ardent Health, Inc. (ARDT) Form 4: Chief Financial Officer Alfred Lumsdaine reported a transaction on 09/25/2025 in which 3,389 shares of the issuer's common stock were disposed of at a price of $13.19 per share. The filing states the shares were withheld to pay taxes upon vesting of restricted stock units. After the reported disposition, the reporting person beneficially owns 211,147 shares, held directly. The form was signed by an attorney-in-fact on 09/30/2025.

Stephen C. Petrovich, Executive Vice President, General Counsel and Assistant Secretary of Ardent Health, Inc. (ARDT), reported a routine share disposition on 09/25/2025. The filing shows 788 shares were withheld to satisfy tax withholding upon vesting of restricted stock units at a closing price of $13.19, and after that transaction Mr. Petrovich directly beneficially owned 718,303 shares. In addition, the filing discloses two family trusts each holding 186,225 shares, which the reporting person disclaims beneficial ownership of except for any pecuniary interest. The form is a standard Section 16 report documenting an internal tax-related share settlement rather than an open-market sale.

David Raynor Byers, Senior Vice President & Chief Accounting Officer of Ardent Health, Inc. (ARDT), reported a routine disposition of common stock on 09/25/2025. The filing shows 524 shares were disposed under Code F (withholding to pay taxes upon vesting of restricted stock units) at a reported price equal to the closing stock price on 09/25/2025 of $13.19. After the withholding, Mr. Byers beneficially owns 111,791 shares directly. The Form 4 was signed by an attorney-in-fact on 09/30/2025.

Ardent Health, Inc. amended its term loan and ABL credit facilities with Bank of America and other lenders. The Term Loan Amendment refinanced outstanding term loans in full, extended the term loan maturity from August 24, 2028 to September 18, 2032, reduced the applicable interest spread by 50 basis points (from Term SOFR+2.75% to Term SOFR+2.25%, and from base rate+1.75% to base rate+1.25%), and expanded fixed-dollar negative covenant baskets. The ABL Amendment aligned certain fixed-dollar negative covenant baskets with the term loan changes but did not extend the ABL maturity or make other material changes. The full amendment texts are filed as exhibits and govern the detailed terms.

Ardent Health, Inc. operates a network of 30 acute care hospitals and approximately 280 sites of care across six states with 1,875 employed and affiliated providers as of June 30, 2025. The company uses a joint-venture model in which it is typically the majority owner and day-to-day operator, partnering with academic and not-for-profit systems to expand market presence and clinical services. EGI-AM Investments, L.L.C. owned approximately 54.0% of outstanding common stock, making EGI-AM the company’s controlling stockholder under NYSE rules. The filing discloses a table of selling stockholders showing large share blocks (for example, 77,246,499 shares representing 54.0%) and various other holders with specified share counts and percentages. The prospectus lists exhibits, underwriting and legal opinions, audit consents from Ernst & Young LLP, and a registration fee table.